First published online December 11, 2006
Journal of Cell Science 119, 2404e (2006)
© The Company of Biologists Limited
NO limit to muscular dystrophy
Muscular dystrophies are untreatable, sometimes fatal, genetic diseases that are characterized by progressive wasting of skeletal muscle. Stem-cell-based therapies, such as the injection of mesoangioblasts (blood-vessel-associated myogenic stem cells), have usually stimulated only limited muscle repair in animal models of muscular dystrophy. But, on p. 5114, Giulio Cossu, Emilio Clementi and co-authors report that ex-vivo treatment of mesoangioblasts with nitric oxide (NO) donors increases their therapeutic efficacy in the
-sarcoglycan-null mouse model of Duchenne muscular dystrophy. NO treatment, they report, enhances the migration of mesoangioblasts to the dystrophic muscles of these mice and helps the mesoangioblasts resist the apoptogenic environment of these muscles and engraft. The authors replicate these beneficial effects of NO in vitro and show that all the effects are GMP-dependent. Finally, they report that NO switches on signalling pathways in the mesoangioblasts that are involved in myogenesis and muscle repair. Thus, the authors conclude, treatment with NO might be a simple way to improve the efficacy of stem-cell therapy for muscle-wasting disorders.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
Related articles in JCS:
- Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy
- Clara Sciorati, Beatriz G. Galvez, Silvia Brunelli, Enrico Tagliafico, Stefano Ferrari, Giulio Cossu, and Emilio Clementi
JCS 2006 119: 5114-5123.
[Abstract]
[Full Text]